How the 2026 Election Affects Behavioral Health Valuations and M&A
By Kevin Taggart, CM&AP, Managing Partner, Mertz Taggart

How will the 2026 election affect behavioral health M&A? Our expectation is continued, selective acquisition activity—not an automatic increase in valuations. Divided government should make additional major Medicaid cuts harder to enact, but it does not reverse existing law or guarantee better reimbursement. For mental health, addiction treatment, autism, and I/DD owners, the practical effect depends on payer mix, state policy, staffing, and the durability of earnings.
Democrats have won control of the House and Senate, with the new Congress taking office in January. President Trump remains in office. Holland & Knight’s pre-election analysis identified the resulting constraint: greater congressional leverage does not make a wholesale reversal of the administration’s healthcare agenda likely.
For an owner considering a sale, the question is what changes the earnings a buyer can reasonably expect your business to generate—and the risks attached to collecting them.
Here is our base case for the next 12–18 months. These are transaction judgments, not forecasts from a quantified election-to-valuation model.
Medicaid: The election does not remove the implementation risk
We expect a Democratic Congress to make another major legislative reduction in Medicaid funding less likely. We would not assume it will quickly reverse restrictions already enacted.
For behavioral health, eligibility administration deserves particular attention. CMS’s June 2026 rule implements work requirements for certain adults in the Medicaid expansion population and specified waiver programs, generally beginning January 1, 2027. It is not a blanket requirement for all Medicaid patients; exemptions include certain disabled or medically frail individuals.
The behavioral health exceptions require care. KFF’s analysis explains that the rule ties medical frailty to a person’s ability to meet the requirements, not simply the presence of a diagnosis. An owner should not assume every patient with a mental health condition or substance use disorder is automatically protected.
Our concern is not that every affected patient stops needing treatment. It is that a patient may have difficulty establishing or maintaining coverage, disrupting treatment and payment.
In a sale, we would examine your actual patient eligibility categories, state implementation, coverage interruptions, denials, and collections. A headline estimate of national coverage losses is not a revenue forecast for your business.
Mental health: More parity attention does not guarantee higher collections
We expect stronger congressional interest in behavioral health access and insurer practices. That should not be modeled as an immediate increase in reimbursement or a reduction in denials.
Mental health parity law remains in place, but the enforcement picture is more complicated than “the new rules took effect.” The Department of Labor’s September 2026 guidance maintains nonenforcement of provisions newly added by the 2024 parity rule while recognizing continuing statutory obligations, including comparative-analysis requirements.
Congressional pressure could influence the debate. It does not itself rewrite insurer contracts, settle litigation, or change an agency’s enforcement policy.
There are also specific bipartisan advocates. Reps. Doris Matsui (D-CA) and August Pfluger (R-TX), with other colleagues, reintroduced the Ensuring Excellence in Mental Health Act in April. The proposal would establish more durable payment arrangements for Certified Community Behavioral Health Clinics, or CCBHCs.
That matters, but it is a model-specific proposal—not a payment increase for every counseling or psychiatry practice. SAMHSA’s CCBHC requirements include comprehensive services, care coordination, and round-the-clock crisis availability.
For a private practice owner, we would still focus on clinician retention, completed visits, contracted rates, authorization requirements, and cash collections. We would not increase the valuation merely because access has bipartisan support.
Addiction treatment: Authorization is not the same as funding
Addiction treatment already has evidence of bipartisan legislative support. Sen. Bill Cassidy (R-LA) helped advance the SUPPORT reauthorization, and Rep. Brett Guthrie (R-KY) sponsored the House legislation that became law on December 1, 2025. The election did not create that support.
The distinction owners should watch is between authorizing a program and funding it. The Congressional Research Service’s September 2026 review states explicitly that the law does not appropriate funds. Renewed program authority is not, by itself, a grant award or dependable provider revenue.
Our expectation is continued negotiation over prevention, treatment, recovery, and workforce programs. For a transaction, we would separate recurring reimbursement from grants and contracts with renewal, transfer, or funding risk.
Marwood Group’s January 2026 public SUD market summary also distinguishes underlying treatment demand from reimbursement variability and financial sustainability. That is the right distinction for an owner: substantial need does not prove your particular program can deliver profitable, collectible care.
We would assess the economics of your actual levels of care, payer relationships, staffing, and referral sources—not treat all addiction treatment businesses as interchangeable.
Telehealth: Coverage and prescribing are different questions
For virtual psychiatry and medication-based addiction treatment, we would not assume that supportive political statements resolve the operating rules.
The DEA’s broad temporary controlled-medication prescribing extension runs through December 31, 2026. The DEA also identifies separate authorities for buprenorphine treatment and certain veterans’ care, each with its own requirements.
That is not the same as a universal expiration of behavioral health telehealth. Whether a visit is covered, whether a clinician may practice across state lines, and whether a controlled medication may be prescribed remotely are separate questions.
Our expectation is that buyers will want a defensible operating plan under the rules applicable to your business. Do not count on an unannounced extension, or assume a change in one authority shuts down every virtual service.
Autism and I/DD: Do not combine different coverage risks
Autism and ABA services
For Medicaid-enrolled children under 21 entitled to Early and Periodic Screening, Diagnostic, and Treatment benefits, the federal EPSDT framework requires coverage of medically necessary services within the specified federal benefit categories. That framework is different from adult waiver-based services. It does not guarantee any provider a particular rate or every requested treatment hour.
In its February 2026 public autism-sector summary, Marwood Group described increasing scrutiny of utilization, billing, reimbursement, and benefit administration, including at PE-backed platforms.
We do not expect the election to eliminate those issues. For an ABA owner, the more useful valuation evidence is support for medical necessity, reliable documentation, delivered versus authorized hours, supervision, clinician capacity, and actual collection experience.
I/DD community and residential supports
For I/DD businesses, identify the funding authority for each service. Do not apply the children’s EPSDT framework to every adult residential, day, or community-support program.
There are concrete advocates for expansion. Sens. Ben Ray Luján (D-NM) and Tim Kaine (D-VA) introduced the HCBS Access Act, proposing a mandatory Medicaid home- and community-based benefit, more funding, and workforce support. Rep. Debbie Dingell (D-MI) introduced the House version.
That is a meaningful policy direction, not an enacted entitlement expansion. Our expectation is more attention to access and workforce capacity, but not an immediate national improvement in I/DD margins. State rates, available program capacity, staffing costs, and service obligations still need to support the earnings being sold.
What does this mean for behavioral health valuations and sale timing?
Our base case is continued buyer interest in businesses with sustainable earnings and a credible operating model, with greater caution where eligibility, reimbursement, staffing, or compliance remains unresolved. We would not promise an election-driven increase in multiples or a specific change in deal volume.
For recent transaction context, see our Q3 2026 Behavioral Health M&A Report. The election is a change in the policy backdrop, not the starting point for the acquisition market.
We would not accelerate a sale because Democrats won Congress, and we would not postpone one simply to wait for a more supportive political environment.
Waiting can make sense if you can identify an achievable improvement that would materially strengthen value: stabilizing clinician capacity, implementing a signed rate increase, reducing denials, improving management depth, or resolving a documented compliance issue.
The test is whether the expected benefit of waiting justifies the operating and personal risk—not whether Washington sounds more favorable to behavioral health.
For preparation, read How to Prepare Your Behavioral Health Business for Sale in 2026.
Frequently asked questions
Will the election increase the value of my behavioral health business?
Not automatically. Our view is that value improves when a change supports sustainable earnings, reduces buyer risk, or strengthens competition for your specific business. Political support alone does not establish any of those outcomes.
Are patients with mental health conditions or addiction exempt from Medicaid work requirements?
Some patients may qualify for exemptions, but a diagnosis alone should not be treated as a blanket exemption. The applicable eligibility category, functional limitations, verification requirements, and state implementation matter. Review the current rules rather than assume all behavioral health revenue is either protected or at risk.
Does stronger mental health parity mean insurers must pay my requested rates?
No. Do not translate support for parity into a guaranteed contract rate, approval of every requested service, or collection of every claim. For a sale, show how your actual payer contracts, authorizations, denials, and collections support the earnings presented.
Considering a sale? If you want to understand how policy exposure, payer mix, or operating performance could affect your business’s value, contact Mertz Taggart for a confidential conversation.
Kevin Taggart, CM&AP, is Managing Partner at Mertz Taggart. The firm advises owners on behavioral health M&A, including mental health, addiction treatment, autism, and I/DD services.
Policy status reviewed November 4, 2026. Expectations about valuations and acquisition activity reflect Mertz Taggart’s judgment, not a guarantee of transaction outcomes.

Comments